Dossier assessment

Nerandomilast (idiopathic pulmonary fibrosis) – Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A26-104
Last updated

Report documents

  1. Extract of dossier assessment

    Nerandomilast (idiopathic pulmonary fibrosis) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 288 kB, DE, not accessible
  2. Dossier assessment

    Nerandomilast (idiopathic pulmonary fibrosis) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 2 MB, DE, not accessible
    DOI-Link
    https://doi.org/10.60584/A26-104

Dossier assessment

Indication:

Adults with idiopathic pulmonary fibrosis (IPF)

Result of dossier assessment:
  • Nerandomilast as add-on therapy to ongoing nintedanib or pirfenidone therapy: added benefit not proven
  • Nerandomilast as add-on therapy to newly initiated pirfenidone or nintedanib therapy or as monotherapy: added benefit not proven (no suitable data)

Project details

Project no.
A26-104
Commission
Commission awarded on 17.08.2026 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Airways and respiratory system
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

DOI

https://doi.org/10.60584/A26-104

Connected Projects

  1. Dossier assessment

    Nerandomilast (progrediente pulmonale Fibrose) – Nutzenbewertung gemäß § 35a SGB V

    Project no.
    A26-103
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form